Novo's Suit Over Compounded Weight Loss Drug Is Tossed
A Florida federal judge has issued an order dismissing Novo Nordisk Inc.'s suit against a Florida independent pharmacy for selling compounded semaglutide, a peptide also found in Ozempic, Novo's blockbuster diabetes drug used off-label for weight loss, ruling that the pharmaceutical company's claim is preempted by the federal Food, Drug and Cosmetic Act.